GENMAB A/S GNMSF news, videos and press releases - Page 5
For more news please use our advanced search feature.
GENMAB A/S GNMSF - More news...
GENMAB A/S GNMSF - More news...
- Genmab and AbbVie Announce Broad Oncology Collaboration
- Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma
- Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis
- Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
- Genmab Announces Data to be Presented at the EHA25 Virtual Congress
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Financial Results for the First Quarter of 2020
- Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma
- CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma
- Genmab Announces Data to be Presented at ASCO20 Virtual Scientific Program
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Files Annual Report with the U.S. Securities and Exchange Commission
- Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and a New Member of Management, and Grant of Restricted Stock Units and Warrants to Employees and a New Member
- Passing of Genmab A/S’ Annual General Meeting
- Genmab A/S Provides Update to Annual General Meeting
- Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer
- Notice to Convene the Annual General Meeting of Genmab A/S
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- U.S. FDA Filing Acceptance and Priority Review for sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis
- Genmab Board of Directors Chairman to Step Down
- Genmab Publishes 2019 Annual Report
- Horizon Therapeutics Secures U.S. FDA Approval for Teprotumumab, for the Treatment of Thyroid Eye Disease (TED)
- Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen
- Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma